Latest Content

Weighing in on The Lancet Diabetes & Endocrinology's expert panel and its division of obesity diagnoses.

Catch up on the top stories in optometry during the week of July 27-31.

PROSE treatment and Mackie stage improvement in neurotrophic keratitis: retrospective study design and primary results.

Maria Sampalis, OD, weighs in on how she has tripled her private practice's growth during her career and how she has used the back to school season as an opportunity to strengthen that growth.

Philip Morgan, BSc, PhD, MCOptom, FAAO, and Lyndon Jones, DSc, PhD, FCOptom, discuss the latest data on contact lens profitability released from the Contact Lens Institute.

Toric, spheric, and multifocal contact lenses are 86%, 79%, and 29% more profitable, respectively, than equivalent glasses-only patients.

Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Jade Coats, OD, FAAO, stated that providing pre- and post-op patient care can provide an opportunity to support ophthalmologists.

Protecting eye health today requires more than regular eye exams and good lighting

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.